Hann, Byron

α-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by α-TGFβ antibody to promote durable rejection and immunity in squamous cell carcinomas

Dodagatta-Marri, E., Meyer, D. S., Reeves, M. Q., Paniagua, R., To, M. D., Binnewies, M., Broz, M. L., Mori, H., Wu, D., Adoumie, M., et al. (2019) · Journal for ImmunoTherapy of Cancer

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 177

KRAS G12C inhibition produces a driver-limited state revealing collateral dependencies

Lou, K., Steri, V., Ge, A. Y., Hwang, Y. C., Yogodzinski, C. H., Shkedi, A. R., Choi, A. L. M., Mitchell, D. C., Swaney, D. L., Hann, B., et al. (2019) · Science Signaling

Protein Kinase Regulation and GTPase SignalingCancer Genomics and Diagnostics

Cited by 175

A covalent inhibitor of K-Ras(G12C) induces MHC class I presentation of haptenated peptide neoepitopes targetable by immunotherapy

Zhang, Z., Rohweder, P. J., Ongpipattanakul, C., Basu, K., Bohn, M.-F., Dugan, E. J., Steri, V., Hann, B., Shokat, K. M., & Craik, C. S. (2022) · Cancer Cell

Immunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkers

Cited by 136

Outgrowth of Drug-Resistant Carcinomas Expressing Markers of Tumor Aggression after Long-term TβRI/II Kinase Inhibition with LY2109761

Connolly, E. C., Saunier, E. F., Quigley, D., Luu, M. T., De Sapio, A., Hann, B., Yingling, J. M., & Akhurst, R. J. (2011) · Cancer Research

TGF-β signaling in diseasesCancer Cells and Metastasis

Cited by 82

Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer

Su, Y., Liu, Y., Behrens, C. R., Bidlingmaier, S., Lee, N.-K., Aggarwal, R., Sherbenou, D. W., Burlingame, A. L., Hann, B. C., Simko, J. P., et al. (2018) · JCI Insight

Prostate Cancer Treatment and ResearchMonoclonal and Polyclonal Antibodies Research

Cited by 82

Surface Proteomics Reveals CD72 as a Target for In Vitro –Evolved Nanobody-Based CAR-T Cells in KMT2A/MLL1 -Rearranged B-ALL

Nix, M. A., Mandal, K., Geng, H., Paranjape, N., Lin, Y.-H. T., Rivera, J. M., Marcoulis, M., White, K. L., Whitman, J. D., Bapat, S. P., et al. (2021) · Cancer Discovery

CAR-T cell therapy researchAcute Lymphoblastic Leukemia research

Cited by 72

Integrin αvβ8 on T cells is responsible for suppression of anti-tumor immunity in multiple syngeneic models and is a promising target for tumor immunotherapy

Dodagatta-Marri, E., Ma, H.-Y., Liang, B., Li, J., Meyer, D. S., Sun, K.-H., Ren, X., Zivak, B., Rosenblum, M. D., Headley, M. B., et al. (2020) · Cell Reports

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 70

A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAFV600E colorectal tumors

Ruiz-Saenz, A., Atreya, C. E., Wang, C., Pan, B., Dreyer, C. A., Brunen, D., Prahallad, A., Muñoz, D. P., Ramms, D. J., Burghi, V., et al. (2023) · Nature Cancer

Colorectal Cancer Treatments and StudiesMelanoma and MAPK Pathways

Cited by 39

Ferrous iron–activatable drug conjugate achieves potent MAPK blockade in KRAS -driven tumors

Jiang, H., Muir, R. K., Gonciarz, R. L., Olshen, A. B., Yeh, I., Hann, B. C., Zhao, N., Wang, Y.-H., Behr, S. C., Korkola, J. E., et al. (2022) · Journal of Experimental Medicine

Protein Kinase Regulation and GTPase SignalingMelanoma and MAPK Pathways

Cited by 33